Previous 10 | Next 10 |
2023-04-03 08:43:08 ET Summary Finch Therapeutics recently made the decision to discontinue the company's Phase 3 trial, lay off 95% of its workforce, and pursue the next path to maximize value for shareholders. As of now, the company has a market cap of $16 million with a cash po...
2023-03-23 16:43:21 ET Finch Therapeutics press release ( NASDAQ: FNCH ): Q4 GAAP EPS of -$0.56. Cash and cash equivalents as of December 31, 2022 was $71.0 million, compared to $133.5 million as of December 31, 2021. Finch expects that the cash and cash equivalents it had...
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today re...
Summary April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff. FNCH is a casualty of setbacks at the beginning of the new medical ...
Finch Therapeutics ( NASDAQ: FNCH ) is discontinuing a phase 3 trial of its bacterial infection drug CP101 and reducing its workforce by ~95%. The company noted that it will discontinue the late-stage study, dubbed PRISM4, of microbiome candidate CP101 in recurrent...
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile ...
Summary After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109. Big focus on SER-155 and other bacterial infections to follow SER-10...
Finch Therapeutics press release ( NASDAQ: FNCH ): Q3 GAAP EPS of -$0.85 misses by $0.45 . Finch’s cash and cash equivalents as of September 30, 2022 were $85.3 million, compared to $133.5 million as of December 31, 2021. Finch believes its cash and cash equival...
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI Topline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” ...
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...
News, Short Squeeze, Breakout and More Instantly...
Finch Therapeutics Group Inc. Company Name:
FNCH Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...